Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in Fibroblasts

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Zhu, Xiaoxia ^a   Liu, Qiong ^a   Wang, Meimei ^b   Liang, Minrui ^a   Yang, Xue ^a   Xu, Xue ^a   Zou, Hejian ^a   Qiu, Jianhua ^c  

^a FUDAN UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; RESVERATROL; S6 KINASE; SIRTUIN 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; AUTACOID; MESSENGER RNA; MTOR PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE; SMALL INTERFERING RNA; STILBENE DERIVATIVE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR RELA;

ACETYLATION; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROBLAST; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; UPREGULATION; ANIMAL; APOPTOSIS; CELL LINE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MAMMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; FIBROBLASTS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MATRIX METALLOPROTEINASE 9; MICE; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIRTUIN 1; STILBENES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055113353     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027081     Document Type: Article

References (77)

1. Kang SY, Kim MH, Lee WI, (2010) Measurement of inflammatory cytokines in patients with rheumatoid arthritis. Korean J Lab Med 30: 301-306.
2. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, et al. (2004) Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 138: 540-546.
3. Hu X, Ho HH, Lou O, Hidaka C, Ivashkiv LB, (2005) Homeostatic role of interferons conferred by inhibition of IL-1-mediated inflammation and tissue destruction. J Immunol 175: 131-138.
4. Hernandez-Pando R, Rook GA, (1994) The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82: 591-595.
5. Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, et al. (2008) Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 180: 3447-3456.
6. Christodoulou C, Choy EH, (2006) Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 6: 13-19.
7. Suryaprasad AG, Prindiville T, (2003) The biology of TNF blockade. Autoimmun Rev 2: 346-357.
8. Ancuta C, Ancuta E, Miu S, Iordache C, Belibou C, et al. (2009) Adalimumab therapy in patients with active rheumatoid arthritis. Rev Med Chir Soc Med Nat Iasi 113: 710-715.
9. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, et al. (2007) Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clin Exp Rheumatol 25: 838-846.
10. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, et al. (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50: 1400-1411.
11. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
12. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, et al. (2008) A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 373: 423-428.
13. Ford J, Jiang M, Milner J, (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463.
14. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, et al. (2007) Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 292: L567-576.
15. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380.
16. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I, (2008) SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177: 861-870.
17. Singh UP, Singh NP, Singh B, Hofseth LJ, Price RL, et al. (2010) Resveratrol (trans-3,5,4′-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodium-induced colitis. J Pharmacol Exp Ther 332: 829-839.
18. Borra MT, Smith BC, Denu JM, (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187-17195.
19. Bishayee A, Waghray A, Barnes KF, Mbimba T, Bhatia D, et al. (2010) Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm Res 27: 1080-1091.
20. Knobloch J, Sibbing B, Jungck D, Lin Y, Urban K, et al. (2010) Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease. J Pharmacol Exp Ther 335: 788-798.
21. Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, et al. (2011) Resveratrol down-regulates interferon-gamma-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem 22: 902-909.
22. Csaki C, Keshishzadeh N, Fischer K, Shakibaei M, (2008) Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochem Pharmacol 75: 677-687.
23. Donnelly LE, Newton R, Kennedy GE, Fenwick PS, Leung RH, et al. (2004) Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 287: L774-783.
24. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B, (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30: 1-6.
25. Holmes-McNary M, Baldwin AS Jr, (2000) Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60: 3477-3483.
26. Manna SK, Mukhopadhyay A, Aggarwal BB, (2000) Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519.
27. Csaki C, Mobasheri A, Shakibaei M, (2009) Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther 11: R165.
28. Kumar A, Sharma SS, (2010) NF-kappaB inhibitory action of resveratrol: a probable mechanism of neuroprotection in experimental diabetic neuropathy. Biochem Biophys Res Commun 394: 360-365.
29. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB, (2010) Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int J Obes (Lond) 34: 1546-1553.
30. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, et al. (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113: 1447-1455.
31. Qiu J, Xu J, Zheng Y, Wei Y, Zhu X, et al. (2010) High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 41: 2077-2082.
32. Ding GJ, Fischer PA, Boltz RC, Schmidt JA, Colaianne JJ, et al. (1998) Characterization and quantitation of NF-kappaB nuclear translocation induced by interleukin-1 and tumor necrosis factor-alpha. Development and use of a high capacity fluorescence cytometric system. J Biol Chem 273: 28897-28905.
33. Shao XT, Feng L, Yao HP, Sun WJ, Zhang LH, (2004) Effect of Triptolide on TNFalpha-induced activation of NF-kappaB and expression of COX-2 and iNOS in human rheumatoid arthritis synovial fibroblasts. 33: 160-165 Zhejiang Da Xue Xue Bao Yi Xue Ban.
34. Boussetta T, Raad H, Letteron P, Gougerot-Pocidalo MA, Marie JC, et al. (2009) Punicic acid a conjugated linolenic acid inhibits TNFalpha-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 4: e6458.
35. Zhang HN, Li L, Gao P, Chen HZ, Zhang R, et al. (2010) Involvement of the p65/RelA subunit of NF-kappaB in TNF-alpha-induced SIRT1 expression in vascular smooth muscle cells. Biochem Biophys Res Commun 397: 569-575.
36. Lee SJ, Kim MM, (2011) Resveratrol with antioxidant activity inhibits matrix metalloproteinase via modulation of SIRT1 in human fibrosarcoma cells. Life Sci 88: 465-472.
37. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, et al. (2011) SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance. Ann Rheum Dis 70: 1866-1873.
38. Tak PP, Firestein GS, (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
39. Ito K, (2007) Impact of post-translational modifications of proteins on the inflammatory process. Biochem Soc Trans 35: 281-283.
40. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130: 440-455.
41. Zhang C, Feng Y, Qu S, Wei X, Zhu H, et al. (2011) Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90: 538-545.
42. Lo SF, Huang CM, Lin HC, Chen WC, Tsai CH, et al. (2008) Cytokine (IL-6) and chemokine (IL-8) gene polymorphisms among rheumatoid arthritis patients in Taiwan. Clin Exp Rheumatol 26: 632-637.
43. Jung-Hynes B, Ahmad N, (2009) Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle 8: 1478-1483.
44. Salminen A, Ojala J, Huuskonen J, Kauppinen A, Suuronen T, et al. (2008) Interaction of aging-associated signaling cascades: inhibition of NF-kappaB signaling by longevity factors FoxOs and SIRT1. Cell Mol Life Sci 65: 1049-1058.
45. Kim YS, Lee YM, Park JS, Lee SK, Kim EC, (2010) SIRT1 modulates high-mobility group box 1-induced osteoclastogenic cytokines in human periodontal ligament cells. J Cell Biochem 111: 1310-1320.
46. Ohguchi K, Itoh T, Akao Y, Inoue H, Nozawa Y, et al. (2010) SIRT1 modulates expression of matrix metalloproteinases in human dermal fibroblasts. Br J Dermatol 163: 689-694.
47. Dvir-Ginzberg M, Gagarina V, Lee EJ, Booth R, Gabay O, et al. (2011) Tumor necrosis factor alpha-mediated cleavage and inactivation of SirT1 in human osteoarthritic chondrocytes. Arthritis Rheum 63: 2363-2373.
48. Zhang J, Lee SM, Shannon S, Gao B, Chen W, et al. (2009) The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest 119: 3048-3058.
49. Gao Z, Ye J, (2008) Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun 376: 793-796.
50. Ishinaga H, Jono H, Lim JH, Kweon SM, Xu H, et al. (2007) TGF-beta induces p65 acetylation to enhance bacteria-induced NF-kappaB activation. EMBO J 26: 1150-1162.
51. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
52. Sun W, Wang W, Kim J, Keng P, Yang S, et al. (2008) Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol 614: 179-186.
53. Banerjee S, Bueso-Ramos C, Aggarwal BB, (2002) Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954.
54. Bereswill S, Munoz M, Fischer A, Plickert R, Haag LM, et al. (2010) Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS One 5: e15099.
55. Lu X, Ma L, Ruan L, Kong Y, Mou H, et al. (2010) Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 7: 46.
56. Chen CJ, Yu W, Fu YC, Wang X, Li JL, et al. (2009) Resveratrol protects cardiomyocytes from hypoxia-induced apoptosis through the SIRT1-FoxO1 pathway. Biochem Biophys Res Commun 378: 389-393.
57. Costa Cdos S, Rohden F, Hammes TO, Margis R, Bortolotto JW, et al. (2010) Resveratrol upregulated SIRT1, FOXO1, and adiponectin and downregulated PPARgamma1-3 mRNA expression in human visceral adipocytes. Obes Surg 21: 356-361.
58. Zhang HS, Zhou Y, Wu MR, Zhou HS, Xu F, (2009) Resveratrol inhibited Tat-induced HIV-1 LTR transactivation via NAD(+)-dependent SIRT1 activity. Life Sci 85: 484-489.
59. Beher D, Wu J, Cumine S, Kim KW, Lu SC, et al. (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74: 619-624.
60. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, et al. (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-8351.
61. Zhang Z, Lowry SF, Guarente L, Haimovich B, (2010) Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J Biol Chem 285: 41391-41401.
62. Kitada M, Kume S, Imaizumi N, Koya D, (2011) Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 60: 634-643.
63. Lan D, Lu M, Sharma S, Mellon PL, Olefsky JM, et al. (2011) Trans-resveratrol inhibits phosphorylation of Smad2/3 and represses FSHbeta gene expression by a SirT1-independent pathway in LbetaT2 gonadotrope cells. Reprod Toxicol 32: 85-92.
64. Pan WW, Li JD, Huang S, Papadimos TJ, Pan ZK, et al. (2010) Synergistic activation of NF-{kappa}B by bacterial chemoattractant and TNF{alpha} is mediated by p38 MAPK-dependent RelA acetylation. J Biol Chem 285: 34348-34354.
65. Quivy V, Van Lint C, (2004) Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol 68: 1221-1229.
66. Chen LF, Greene WC, (2003) Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation. J Mol Med 81: 549-557.
67. Chen LF, Williams SA, Mu Y, Nakano H, Duerr JM, et al. (2005) NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 25: 7966-7975.
68. Chen LF, Mu Y, Greene WC, (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21: 6539-6548.
69. Schaeffer V, Abrass CK, (2010) Mechanisms and control of protein translation in the kidney. Am J Nephrol 31: 189-201.
70. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
71. Lorne E, Zhao X, Zmijewski JW, Liu G, Park YJ, et al. (2009) Participation of mammalian target of rapamycin complex 1 in Toll-like receptor 2- and 4-induced neutrophil activation and acute lung injury. Am J Respir Cell Mol Biol 41: 237-245.
72. Lisi L, Navarra P, Feinstein DL, Dello Russo C, (2011) The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation 8: 1.
73. Plaisance I, Morandi C, Murigande C, Brink M, (2008) TNF-alpha increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3K, and MEK. Am J Physiol Endocrinol Metab 294: E241-250.
74. Glantschnig H, Fisher JE, Wesolowski G, Rodan GA, Reszka AA, (2003) M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 10: 1165-1177.
75. Lang CH, Pruznak AM, Frost RA, (2005) TNFalpha mediates sepsis-induced impairment of basal and leucine-stimulated signaling via S6K1 and eIF4E in cardiac muscle. J Cell Biochem 94: 419-431.
76. Bonegio RG, Fuhro R, Wang Z, Valeri CR, Andry C, et al. (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16: 2063-2072.
77. Liu M, Agreda P, Crow M, Racusen L, Rabb H, (2009) Effects of delayed rapamycin treatment on renal fibrosis and inflammation in experimental ischemia reperfusion injury. Transplant Proc 41: 4065-4071.